About cidara therapeutics inc - CDTX
Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.
CDTX At a Glance
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive
San Diego, California 92121
| Phone | 1-858-752-6170 | Revenue | 1.28M | |
| Industry | Pharmaceuticals: Other | Net Income | -168,028,000.00 | |
| Sector | Health Technology | Employees | 38 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CDTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 133.865 |
| Price to Book Ratio | 1.802 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.241 |
| Enterprise Value to Sales | -17.194 |
| Total Debt to Enterprise Value | -0.163 |
CDTX Efficiency
| Revenue/Employee | 33,552.632 |
| Income Per Employee | -4,421,789.474 |
| Receivables Turnover | 0.753 |
| Total Asset Turnover | 0.009 |
CDTX Liquidity
| Current Ratio | 4.253 |
| Quick Ratio | 4.253 |
| Cash Ratio | 3.959 |
CDTX Profitability
| Gross Margin | 81.725 |
| Operating Margin | -7,154.431 |
| Pretax Margin | -13,356.157 |
| Net Margin | -13,178.667 |
| Return on Assets | -119.878 |
| Return on Equity | -219.591 |
| Return on Total Capital | -102.042 |
| Return on Invested Capital | -212.057 |
CDTX Capital Structure
| Total Debt to Total Equity | 2.19 |
| Total Debt to Total Capital | 2.143 |
| Total Debt to Total Assets | 1.659 |
| Long-Term Debt to Equity | 1.184 |
| Long-Term Debt to Total Capital | 1.159 |